Trial Profile

A study evaluating cost-effectiveness and quality-adjusted life-year (QALY) of obinutuzumab chemotherapy followed by Obinutuzumab maintenance in public Chilean health system for the treatment advanced Non-Hodgkin Follicular Lymphoma

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 22 May 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Obinutuzumab (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
Indications Non-Hodgkin's lymphoma
Focus Therapeutic Use

22 May 2020 New trial record
20 May 2020 Results presented at the 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com